Latham & Watkins Advises the Underwriters in Reneo Pharmaceuticals’ Initial Public Offering

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, has announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of US$15 per share, for total gross proceeds of approximately US$93.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Reneo.

Latham & Watkins LLP represents the underwriters in the offering with a corporate deal team led by Bay Area partner Brian Cuneo and San Diego partner Matt Bush, with Bay Area associates Richard Kim, Raul Gonzalez and Heather Durham. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang; on intellectual property matters by Bay Area/San Diego partner Chris Hazuka, with San Diego associates Robert Yeh and Michael Sweeney; on benefits and compensation matters by Bay Area partner Ashley Wagner; and on tax matters by Bay Area partner Grace Lee.